Download presentation
Presentation is loading. Please wait.
Published byRobert Karlsen Modified over 5 years ago
1
The influence of metabolic syndrome on hemodialysis access patency
Clinton D. Protack, MD, Akhilesh Jain, MD, Penny Vasilas, RN, Alan Dardik, MD, PhD Journal of Vascular Surgery Volume 56, Issue 6, Pages (December 2012) DOI: /j.jvs Copyright © Terms and Conditions
2
Fig 1 Survival rates for all patients at 6, 12, and 24 months were 93%, 87%, and 73%, respectively. Kaplan-Meier analysis showed patients with metabolic syndrome (MetS) experienced decreased freedom from secondary patency failure compared with patients without MetS (No-MetS). Error bars are omitted for clarity. Standard error did not exceed 10% at all time intervals analyzed. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © Terms and Conditions
3
Fig 2 Freedom from primary patency failure for all patients at 6, 12, and 24 months was 47%, 24%, and 8%, respectively. No difference was identified between groups. Error bars are omitted for clarity. Standard error did not exceed 10% at all time intervals analyzed. MetS, Metabolic syndrome; No-MetS, no metabolic syndrome. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © Terms and Conditions
4
Fig 3 Freedom from secondary patency failure for all patients at 6, 12, and 24 months was 69%, 53%, and 38%, respectively. By Kaplan-Meier analysis, patients with metabolic syndrome (MetS) experienced decreased freedom from secondary patency failure compared with patients without MetS (No-MetS). Error bars are omitted for clarity. Standard error did not exceed 10% at all time intervals analyzed. Journal of Vascular Surgery , DOI: ( /j.jvs ) Copyright © Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.